Це пост з рекомендованої групи
Advances and Challenges in Tuberculosis Vaccine and Treatment Development
Tuberculosis (TB) remains a major infectious disease worldwide, caused by Mycobacterium tuberculosis. Current treatment relies on a multi-drug regimen lasting several months. Drug-resistant strains have created urgency for improved vaccines and therapies.
The BCG vaccine offers moderate protection mainly for children, but its effectiveness in adults is limited. Recent research focuses on developing next-generation TB vaccines that provide stronger protection against pulmonary TB. Strategies include viral vector vaccines, protein subunit formulations, and whole-cell inactivated vaccines.
Treatment innovations involve new drugs such as bedaquiline and pretomanid, which target resistant TB strains. Shortened treatment regimens and combination therapy continue to show promise. Diagnostic tools such as molecular testing, skin tests, and interferon-release assays support early detection.
A major challenge remains adherence, as lengthy treatments increase the risk of incomplete therapy and resistance. Global health programs emphasize patient education, monitoring, and accessible treatment services.
FAQQ1: Why is TB difficult to treat?The bacteria grow slowly…